Catalyst Pharmaceuticals
- Kelly Wilson
- June 8, 2026
- No Comments
A biopharmaceutical company committed to improving the lives of patients living with rare diseases. Please visit https://www.yourcatalystpathways.com/
A biopharmaceutical company committed to improving the lives of patients living with rare diseases. Please visit https://www.yourcatalystpathways.com/
Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Founded on the belief that immunotherapy made from a patient’s own cells will transform disease treatment, Dendreon has worked tirelessly to make the fight against cancer personal. Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy to…
Northstar by BillionToOne is a blood-based liquid biopsy platform that delivers ultra-sensitive genomic and methylation analysis to support personalized cancer care. Powered by proprietary QCT™ technology, Northstar Select® provides comprehensive genomic profiling to guide therapy selection, while Northstar Response® enables real-time monitoring of treatment efficacy through tumor-specific methylation tracking. Together, they offer a seamless, non-invasive…
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full…
About Iovance Biotherapeutics Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance…
Immunocore, LLC is a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases.
About Us AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in…
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™…
We Are Apellis We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven…
Blue Earth Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a recognized leader in the development and commercialization of novel PET radiopharmaceuticals to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by proven experts in nuclear medicine, who have expanded…
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Coherus Oncology is focused on developing and commercializing a diversified portfolio of immuno-oncology therapies. The advancement of multiple clinical stage candidates underscores our commitment to immuno-oncology treatments while the biosimilar business enables us to provide better access to therapy for patients with life-altering illnesses. About Coherus Solutions™ Coherus Oncology is committed to supporting patients with…
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s clinical development programs span multiple disease targets including chronic immune thrombocytopenia, autoimmune hemolytic anemia and others. Rigel’s first FDA approved product…
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical…
Sun Pharma is a leading global pharmaceutical company, providing high-quality medicines trusted by patients. Every day, we help millions of Americans through our diverse portfolio of Innovative Medicines, Generics and Consumer Healthcare products. Our local manufacturing and distribution enables delivery of high-quality therapies that meet the highest regulatory standards. UNLOXCYT SUPPORT is here to…
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune® – the TTFields delivery system for glioblastoma (GBM) – was launched in the U.S. for the treatment of recurrent…
About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it…
Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more. https://www.exelixis.com.
Biotheranostics, Inc. represents the oncology portfolio within the Diagnostic Solutions division of Hologic, Inc. The CLIA certified, CAP accredited laboratory provides two proprietary, highly differentiated molecular diagnostic tests for breast and metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID, respectively. Breast Cancer Index (BCI) Breast Cancer Index (BCI) is the only genomic test recognized…
Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which…
Products, People and Programs Making a Difference For over 150 years Bayer has been an innovation company rooted in science. Our presence in the U.S. harkens back to the mid-19th century as a chemical company making dyes in Albany, NY. However, by the late-19th century we moved into the healthcare field with the introduction of…
© 2021 FLASCO | Premium Website Design by The HDG